<DOC>
	<DOC>NCT00537511</DOC>
	<brief_summary>The purpose of this study is to determine the maximum tolerated dose and safety of CC-4047 (pomalidomide) given in combination with cisplatin and etoposide in patients with extensive disease small cell lung cancer.</brief_summary>
	<brief_title>A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Small Cell</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>signature of informed consent Age &gt;= 18 histologically or cytologically confirmed small cell lung cancer (SCLC) extensive stage SCLC Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2 brain metastases that are asymptomatic and do not require steroid control females of child bearing potential must use two forms of birth control pregnant or lactating females prior use of cytotoxic chemotherapy surgery within 14 days of study radiation within 14 days of study prior therapy with CC4047 (pomalidomide), lenalidomide or thalidomide concurrent use or anticipated use of anticancer agents absolute neutrophil count (ANC) &lt; 1500/mm^3 platelets &lt; 100 x 10^3/ÂµL serum creatinine &gt;2.5 mg/dL serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) &gt; 3.0 x upper limit of normal (ULN) serum total bilirubin &gt; 1.8 mg/dL uncontrolled hypercalcemia creatinine clearance &lt;50 mL/min uncontrolled hypertension neuropathy &gt;= grade 2 body mass index (BMI) &gt;= 40 any other active invasive malignancy requiring treatment known chronic infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) inability or unwillingness to comply with birth control requirements</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>